Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company's lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium. Show more
Rue Edouard Belin 12, Mont-Saint-Guibert, 1435, Belgium
Market Cap
144.1M
52 Wk Range
$2.76 - $8.64
Previous Close
$3.30
Open
$3.30
Volume
21,267
Day Range
$3.10 - $3.30
Enterprise Value
145.1M
Cash
48.0M
Avg Qtr Burn
-13.24M
Insider Ownership
37.04%
Institutional Own.
21.41%
Qtr Updated
12/31/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|